Evidence map›Paper›PMID 40427061›Full record

ArticleBiomedicines2025

Dual Inhibition of HIF-1α and HIF-2α as a Promising Treatment for VHL-Associated Hemangioblastomas: A Pilot Study Using Patient-Derived Primary Cell Cultures.

Ana B Perona-Moratalla, Blanca Carrión, Karina Villar Gómez de Las Heras, Lourdes Arias-Salazar, Blanca Yélamos-Sanz, Tomás Segura, Gemma Serrano-Heras

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ana B Perona-MoratallaDepartment of Neurology, General University Hospital of Albacete, Hermanos Falcó, 37, 02008 Albacete, Spain.ORCID 0000-0002-6804-331X
Blanca CarriónResearch Unit, General University Hospital of Albacete, Laurel, s/n, 02008 Albacete, Spain.
Karina Villar Gómez de Las HerasEmergency and Medical Transport Management, Castilla-La Mancha Health Service (SESCAM), 45071 Toledo, Spain.
Lourdes Arias-SalazarResearch Unit, General University Hospital of Albacete, Laurel, s/n, 02008 Albacete, Spain.
Blanca Yélamos-SanzResearch Unit, General University Hospital of Albacete, Laurel, s/n, 02008 Albacete, Spain.
Tomás SeguraDepartment of Neurology, General University Hospital of Albacete, Hermanos Falcó, 37, 02008 Albacete, Spain.ORCID 0000-0003-3625-0987
Gemma Serrano-HerasResearch Unit, General University Hospital of Albacete, Laurel, s/n, 02008 Albacete, Spain.ORCID 0000-0001-9368-4832

Funding

Fundación Hospital Nacional de Parapléjicos-Institute of Health Research of Castilla-La Mancha (IDISCAM) EMERFundación Hospital Nacional de Parapléjicos-Institute of Health Research of Castilla-La Mancha (IDISCAM) Programa Investigo (2022-2025)Ministry of Health, Social Services, and Equality, according to the agreement of the Interterritorial Council of the National Health System (SNS) for the distribution of funds to the Autonomous Communities. Strategies for Rare Diseases
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

acriflavinecellular proliferative patternshemangioblastomaHIF-1αHIF-2αhypoxia-inducible factorsinhibitorneurosurgerytargeted therapytherapeutic opportunitiesVon Hippel-Lindau disease

Identifiers

PMID40427061
PMCPMC12108798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.